Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma

• Published in: Clinical cancer research Vol. 22; no. 14; pp. 3593 - 3605
• Main Authors: Xu-Monette, Zijun Y., Deng, Qipan, Manyam, Ganiraju C., Tzankov, Alexander, Li, Ling, Xia, Yi, Wang, Xiao-xiao, Zou, Dehui, Visco, Carlo, Dybkær, Karen, Li, Jun, Zhang, Li, Liang, Han, Montes-Moreno, Santiago, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W.L., van Krieken, J. Han, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J.M., Parsons, Ben M., Møller, Michael B., Wang, Sa A., Miranda, Roberto N., Piris, Miguel A., Winter, Jane N., Medeiros, L. Jeffrey, Li, Yong, Young, Ken H.
• Format: Journal Article
• Language: English
• Published: United States 15.07.2016
• Subjects: Antibodies, Monoclonal, Murine-Derived - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cohort Studies; Cyclophosphamide - therapeutic use; Doxorubicin - therapeutic use; Female; Humans; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - genetics; Male; Middle Aged; Mutation - drug effects; Mutation - genetics; Prednisone - therapeutic use; Proto-Oncogene Proteins c-myc - genetics; Translocation, Genetic - drug effects; Translocation, Genetic - genetics; Tumor Suppressor Protein p53 - genetics; Vincristine - therapeutic use

Purpose: MYC is a critical driver oncogene in many cancers, and its deregulation in the forms of translocation and overexpression has been implicated in lymphomagenesis and progression of diffuse large B-cell lymphoma (DLBCL). The MYC mutational profile and its roles in DLBCL are unknown. This study...